TGFB1 and colitis: ACE-Is prevented the generation of proinflammatory cytokines in mouse models of colitis and colonic fibrosis, most likely through inhibiting the TGF-β signaling pathway, paving the way for an innovative inflammatory bowel disease treatment [34].